What the Skin Lets In, and What It Doesn't

The short version

Topical Peptides is a reading desk, not a store. Peptides are short chains of amino acids — the same building blocks in every protein in the body, just far shorter — and the question that decides almost everything about how a given peptide gets studied is simple: can it actually get where it needs to go?

This desk uses three peptides to answer that from three angles. GHK-Cu is unusual because researchers have directly measured it crossing the outer layer of human skin, which is why it shows up in topical serums. Semaglutide and thymosin alpha-1 cannot take that route: one is built for the bloodstream, needing a once-weekly injection or a specially engineered tablet; the other is a subcutaneously injected immune signal. Read together, the three are not really unrelated case studies — they are one lesson in peptide pharmacology, told three ways. Nothing here is medical advice, and no dose is ever recommended, only what was studied and how.

What are research peptides?

Peptides sit at the small end of the protein family — usually fewer than 50 amino acids strung together, versus the hundreds or thousands in a full protein. That size matters enormously for how they behave in and on the body. Small size can help a molecule slip past some biological barriers, but it also means peptides are usually broken down quickly by enzymes unless they are chemically modified to resist it.

The three peptides gathered here span a wide range of what 'research peptide' means in practice. GHK-Cu occurs naturally in the body — it is released when type I collagen breaks down — and is also sold as a legal cosmetic ingredient; the injectable, systemic use some communities describe is unapproved and unstudied in humans. Semaglutide and thymosin alpha-1, by contrast, are approved pharmaceutical drugs in various jurisdictions, built and tested through formal clinical-trial programs. 'Research peptide' is therefore not one single regulatory category — it describes very different scientific and legal situations, and this desk is careful to say, compound by compound, which situation applies.

Topically and transdermally studied: why delivery is the first fundamental

Every peptide on this desk illustrates the same underlying fact from a different side: a peptide's usefulness is inseparable from how it crosses a biological barrier.

GHK-Cu is the clearest topical case. Human skin-penetration studies have measured the intact GHK-Cu tripeptide moving through dermatomed skin at a defined permeability rate, with a measurable fraction retained in the dermis as a slow-release depot ^[5]. That is a rare, directly quantified transdermal delivery story — most peptides never get that kind of skin-crossing data because they simply are not studied that way.

Semaglutide sits at the opposite extreme. Its oral tablet formulation required pairing the peptide with an absorption-enhancing co-formulant just to reach roughly 0.4-1% oral bioavailability ^[14], and the far more common route in its clinical-trial program is a once-weekly subcutaneous injection, enabled by a fatty-acid side chain that extends its time in the bloodstream to roughly a week.

Thymosin alpha-1 is injectable only, delivered subcutaneously in every clinical study that established its dosing and safety profile ^[14]. There is no topical or oral route anywhere in its evidence base.

Reading these three together turns 'how is this peptide taken' from a footnote into the organizing question it actually is. See how they compare side by side.

A note on how this desk reads the literature

Topical Peptides is a cross-referenced literature digest, not a single-compound blog. Each peptide page summarizes the peer-reviewed record for that compound, cites it by number, and points to one shared references list that aggregates every source used across all three. GHK-Cu's evidence base is a mix of small human topical trials, in vitro fibroblast work, and gene-expression analyses, much of it originating from a small circle of investigators — this desk says so plainly rather than inflating the claims. Semaglutide's evidence base is the deepest of the three: multi-thousand-participant randomized trials across several indications. Thymosin alpha-1's picture is the most mixed — decades of small-to-moderate trials plus one large, rigorous, and null 2025 sepsis trial that meaningfully tempered earlier optimism. Where the evidence is thin, phase-limited, or contested, the text says so in the same sentence as the finding, not in a footnote.